Literature DB >> 2499662

Inhibitory and excitatory amino acids in cerebrospinal fluid of chronic epileptic patients.

A Pitkänen1, R Matilainen, T Halonen, R Kutvonen, P Hartikainen, P Riekkinen.   

Abstract

We studied the levels of excitatory and inhibitory amino acids in the cerebrospinal fluid (CSF) of 28 epileptic patients (24 with partial type seizures, 4 with primary generalized seizures) and 12 controls. The levels of aspartate were 63% (p less than 0.01), glutamine 129% (p less than 0.001), and homocarnosine 127% (p less than 0.005) that of controls. The concentrations of glutamate, asparagine, total GABA, free GABA, taurine, and glycine did not differ between epileptic patients and controls. Patients with partial epilepsy had a pattern of amino acids in CSF similar to that in patients with primary generalized seizures. In the present study we did not observe increased excitation or decreased inhibition in the seizure-active brains of epileptics, as far as the CSF levels of amino acids reflect their levels in the brain.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499662     DOI: 10.1007/bf01260507

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  29 in total

1.  Free amino acid levels in the cerebrospinal fluid of normal humans and their variation in cases of epilepsy and Spielmeyer-Vogt-Batten disease.

Authors:  C M Plum
Journal:  J Neurochem       Date:  1974-09       Impact factor: 5.372

2.  Free amino acids of the cerebrospinal fluid and epileptogenesis.

Authors:  V K Pozdeev; A P Il'in
Journal:  Hum Physiol       Date:  1978 Jan-Feb

3.  Role of the substantia nigra in GABA-mediated anticonvulsant actions.

Authors:  K Gale
Journal:  Adv Neurol       Date:  1986

Review 4.  Alterations of GABA-mediated synaptic transmission in human epilepsy.

Authors:  K G Lloyd; L Bossi; P L Morselli; C Munari; M Rougier; H Loiseau
Journal:  Adv Neurol       Date:  1986

5.  Amino acid metabolism in the brain with convulsive disorders. Part 3: Free amino acid patterns in cerebrospinal fluid in infants and children with convulsive disorders.

Authors:  T Honda
Journal:  Brain Dev       Date:  1984       Impact factor: 1.961

6.  Increased concentrations of aspartic acid in the cerebrospinal fluid of patients with epilepsy and trigeminal neuralgia: an effect of medication?

Authors:  B Engelsen; S Elsayed
Journal:  Acta Neurol Scand       Date:  1984-08       Impact factor: 3.209

7.  Enzyme changes in actively spiking areas of human epileptic cerebral cortex.

Authors:  A Sherwin; F Quesney; S Gauthier; A Olivier; Y Robitaille; P McQuaid; C Harvey; N van Gelder
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

8.  Levels of gamma-aminobutyric acid in cerebrospinal fluid in various neurologic disorders.

Authors:  N V Manyam; L Katz; T A Hare; J C Gerber; M H Grossman
Journal:  Arch Neurol       Date:  1980-06

9.  Amino acid abnormalities in epileptogenic foci.

Authors:  T L Perry; S Hansen
Journal:  Neurology       Date:  1981-07       Impact factor: 9.910

10.  Changes in regional brain levels of amino acid putative neurotransmitters after prolonged treatment with the anticonvulsant drugs diphenylhydantoin, phenobarbitone, sodium valproate, ethosuximide, and sulthiame in the rat.

Authors:  P N Patsalos; P T Lascelles
Journal:  J Neurochem       Date:  1981-02       Impact factor: 5.372

View more
  3 in total

1.  N-Acetyl-aspartylglutamate (NAAG) in human cerebrospinal fluid: Determination by high performance liquid chromatography, and influence of biological variables.

Authors:  V Brovia; A Ricciardi; L Barbeito
Journal:  Amino Acids       Date:  1995-06       Impact factor: 3.520

Review 2.  Dogs as a Natural Animal Model of Epilepsy.

Authors:  Wolfgang Löscher
Journal:  Front Vet Sci       Date:  2022-06-22

3.  Plasma and cerebrospinal fluid amino acids in epileptic patients.

Authors:  Sirpa Rainesalo; Tapani Keränen; Johanna Palmio; Jukka Peltola; Simo S Oja; Pirjo Saransaari
Journal:  Neurochem Res       Date:  2004-01       Impact factor: 3.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.